Home › Skin Conditions › North Carolina › Charlotte
Skin Conditions clinical trials in Charlotte, NC
4 studies for Skin Conditions are looking for participants at sites in and around Charlotte (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
RecruitingPhase 3
- Onsite Clinical Solutions, LLC, Huntersville · 13 mi away
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
RecruitingPhase 3
- Dermatology Specialists of Charlotte, Charlotte
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
RecruitingPhase 3
- Onsite Clinical Solutions, LLC, Huntersville · 13 mi away
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RecruitingPhase 2
- Inmagene Site 20, Charlotte
About Skin Conditions
Your skin is your body's largest organ. It covers and protects your body. Learn about skin conditions, including causes, symptoms, and treatment.
More about Skin Conditions on MedlinePlus
Skin Conditions trials in other cities
- Indianapolis, IN6 studies
- Portland, OR5 studies
- Miami, FL5 studies
- Birmingham, AL5 studies
- Los Angeles, CA5 studies
- Phoenix, AZ5 studies
- Washington, DC4 studies
- Hollywood, FL4 studies
- Boston, MA4 studies
- New York City, NY4 studies
- Lewisville, TX4 studies
- Santa Clarita, CA4 studies
Other studies in Charlotte
- Cancer (all types)29 studies
- Breast Cancer22 studies
- Non-Small Cell Lung Cancer22 studies
- Multiple Myeloma21 studies
- Acute Myeloid Leukemia18 studies
- Ovarian Cancer16 studies
- Obesity16 studies
- Colorectal Cancer15 studies
- Overweight15 studies
- Metastatic Cancer12 studies
- Heart Failure12 studies
- Head and Neck Squamous Cell Carcinoma11 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.